Nippon Shinyaku licenses NS-025 rights to Aquelys in exclusive worldwide deal

  • Nippon Shinyaku signed an exclusive license with Aquelys Therapeutics granting worldwide rights to develop, manufacture, commercialize NS-025.
  • Nippon Shinyaku retained rights to develop, commercialize NS-025 for certain indications in Japan.
  • Aquelys will advance NS-025 into studies targeting Sjögren’s-related xerostomia; the compound is in Phase 1 under Nippon Shinyaku.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.